Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Mr. Patrick D. WalshInsider | -13,97k | 1,13M | Verkauf | 80,63 - 80,75 | 38,43k | -26,66% |
| 2026-05-12 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -459,00 | 36,36k | Verkauf | 79,21 | 38,27k | -1,19% |
| 2026-05-12 | Mr. Ori GutwergSVP of Generics | -2,77k | 220,37k | Verkauf | 79,50 | 78,70k | -3,40% |
| 2026-05-11 | Mr. Nikhil LalwaniPresident, CEO & Director | -55,00k | 4,27M | Verkauf | 77,57 | 349,89k | -13,58% |
| 2026-05-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 39,08k | Automatic Disposition | 78,16 | 78,39k | -0,63% |
| 2026-04-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 38,98k | Automatic Disposition | 77,95 | 78,89k | -0,63% |
| 2026-03-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 36,31k | Automatic Disposition | 72,62 | 79,39k | -0,63% |
| 2026-03-11 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -4,77k | 357,47k | Verkauf | 74,91 | 38,73k | -10,97% |
| 2026-03-13 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -3,16k | 226,53k | Automatic Disposition | 71,64 | 91,31k | -3,35% |
| 2026-03-06 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -5,72k | 424,62k | Automatic Disposition | 74,18 - 74,22 | 94,47k | -5,71% |
| 2026-03-07 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -3,31k | 245,37k | Sale to Issuer | 74,04 | 94,47k | -3,39% |
| 2026-03-07 | Mr. Nikhil LalwaniPresident, CEO & Director | -17,06k | 1,26M | Sale to Issuer | 74,04 | 404,89k | -4,04% |
| 2026-03-07 | Mr. Ori GutwergSVP of Generics | -3,31k | 245,37k | Sale to Issuer | 74,04 | 81,47k | -3,91% |
| 2026-03-06 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -6,57k | 488,47k | Automatic Disposition | 74,13 - 75,00 | 51,95k | -11,23% |
| 2026-03-07 | Mr. Stephen P. CareySenior VP of Finance & CFO | -5,15k | 381,31k | Sale to Issuer | 74,04 | 180,39k | -2,78% |
| 2026-03-05 | Mr. Stephen P. CareySenior VP of Finance & CFO | -3,31k | 85,81k | Derivative Exercise and Sale | 49,51 - 75,42 | 185,54k | - |
| 2026-03-05 | Mr. Stephen P. CareySenior VP of Finance & CFO | -4,00k | 302,24k | Verkauf | 75,56 | 185,54k | -2,11% |
| 2026-03-02 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -417,00 | 30,86k | Automatic Disposition | 74,00 | 103,51k | -0,40% |
| 2026-03-03 | Mr. Ori GutwergSVP of Generics | -2,06k | 157,59k | Verkauf | 76,50 | 84,78k | -2,37% |
| 2026-03-03 | Mr. Patrick D. WalshInsider | -6,00k | 445,38k | Verkauf | 74,23 | 52,41k | -10,27% |
| 2026-02-28 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -628,00 | 46,41k | Sale to Issuer | 73,90 | 43,50k | -1,42% |
| 2026-02-28 | Mr. Nikhil LalwaniPresident, CEO & Director | -12,22k | 902,84k | Sale to Issuer | 73,90 | 421,95k | -2,81% |
| 2026-02-28 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -2,22k | 164,13k | Sale to Issuer | 73,90 | 103,93k | -2,09% |
| 2026-02-28 | Mr. Ori GutwergSVP of Generics | -2,22k | 164,13k | Sale to Issuer | 73,90 | 86,84k | -2,49% |
| 2026-02-28 | Mr. Stephen P. CareySenior VP of Finance & CFO | -2,77k | 204,92k | Sale to Issuer | 73,90 | 189,54k | -1,44% |
| 2026-02-28 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -1,56k | 114,91k | Sale to Issuer | 73,90 | 79,89k | -1,91% |
| 2026-02-28 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,56k | 114,91k | Sale to Issuer | 73,90 | 58,52k | -2,59% |
| 2026-02-28 | Mr. Chad GassertSVP of Corporate Development & Strategy | -2,22k | 164,13k | Sale to Issuer | 73,90 | 233,41k | -0,94% |
| 2026-02-19 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -3,81k | 296,50k | Automatic Disposition | 77,53 - 77,99 | 49,26k | -7,19% |
| 2026-02-20 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -5,32k | 415,30k | Automatic Disposition | 78,02 | 84,84k | -5,90% |
| 2026-02-12 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -1,05k | 80,93k | Sale to Issuer | 76,70 - 77,36 | 38,11k | -2,68% |
| 2026-02-12 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -7,03k | 538,30k | Automatic Disposition | 76,55 | 90,16k | -7,23% |
| 2026-02-12 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -5,58k | 429,27k | Sale to Issuer | 76,70 - 77,36 | 90,16k | -5,82% |
| 2026-02-12 | Mr. Nikhil LalwaniPresident, CEO & Director | -21,99k | 1,69M | Sale to Issuer | 76,70 - 77,36 | 358,57k | -5,78% |
| 2026-02-12 | Mr. Ori GutwergSVP of Generics | -3,66k | 282,20k | Sale to Issuer | 76,70 - 77,36 | 76,09k | -4,59% |
| 2026-02-12 | Mr. Chad GassertSVP of Corporate Development & Strategy | -3,33k | 256,16k | Sale to Issuer | 76,70 - 77,36 | 224,51k | -1,46% |
| 2026-02-12 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -2,47k | 190,30k | Sale to Issuer | 76,70 - 77,36 | 53,08k | -4,45% |
| 2026-02-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 38,40k | Automatic Disposition | 76,80 | 67,55k | -0,73% |
| 2026-02-12 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -3,31k | 255,28k | Sale to Issuer | 76,70 - 77,36 | 67,55k | -4,68% |
| 2026-02-12 | Mr. Stephen P. CareySenior VP of Finance & CFO | -5,28k | 406,36k | Sale to Issuer | 76,70 - 77,36 | 170,08k | -3,01% |
| 2026-02-11 | Mr. Stephen P. CareySenior VP of Finance & CFO | -5,50k | 419,60k | Sale to Issuer | 76,25 | 175,36k | -3,04% |
| 2026-02-11 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -3,01k | 229,59k | Sale to Issuer | 76,25 | 71,36k | -4,05% |
| 2026-02-11 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -3,02k | 230,05k | Sale to Issuer | 76,25 | 55,55k | -5,15% |
| 2026-02-11 | Mr. Chad GassertSVP of Corporate Development & Strategy | -4,27k | 325,51k | Sale to Issuer | 76,25 | 227,84k | -1,84% |
| 2026-02-11 | Mr. Ori GutwergSVP of Generics | -4,27k | 325,36k | Sale to Issuer | 76,25 | 79,76k | -5,08% |
| 2026-02-11 | Mr. Nikhil LalwaniPresident, CEO & Director | -30,66k | 2,34M | Sale to Issuer | 76,25 | 380,56k | -7,46% |
| 2026-02-11 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -4,55k | 346,63k | Sale to Issuer | 76,25 | 102,77k | -4,24% |
| 2026-02-11 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -1,76k | 134,35k | Sale to Issuer | 76,25 | 39,16k | -4,31% |
| 2026-02-11 | Mr. Muthusamy ShanmugamHead of R&D, COO of New Jersey Operations & Director | -2,90k | 220,97k | Sale to Issuer | 76,25 | 71,42k | -3,90% |
| 2026-01-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 42,17k | Automatic Disposition | 84,33 | 74,37k | -0,67% |
| 2025-12-18 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,62k | 133,65k | Automatic Disposition | 82,40 | 58,56k | -2,69% |
| 2025-12-12 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 32,93k | Automatic Disposition | 82,32 | 74,87k | -0,53% |
| 2025-12-05 | Dr. Renee P. TannenbaumIndependent Director | -1,80k | 146,07k | Verkauf | 81,15 | 25,16k | -6,68% |
| 2025-11-13 | Mr. Patrick D. WalshInsider | -8,64k | 750,90k | Verkauf | 86,88 | 58,41k | -12,89% |
| 2025-11-13 | Mr. Patrick D. WalshInsider | -3,00k | 0,00 | Other Disposition | - | 58,41k | -4,89% |
| 2025-11-12 | Mr. Chad GassertSVP of Corporate Development & Strategy | -14,64k | 1,30M | Verkauf | 89,07 | 232,11k | -5,93% |
| 2025-11-13 | Mr. Chad GassertSVP of Corporate Development & Strategy | -94,00 | 8,27k | Verkauf | 88,00 | 232,11k | -0,04% |
| 2025-11-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 34,91k | Automatic Disposition | 87,27 | 75,27k | -0,53% |
| 2025-10-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 36,04k | Automatic Disposition | 90,09 | 75,67k | -0,53% |
| 2025-09-19 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1.000,00 | 98,04k | Automatic Disposition | 98,04 | 60,19k | -1,63% |
| 2025-09-12 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 39,37k | Automatic Disposition | 98,42 | 76,07k | -0,52% |
| 2025-09-12 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,71k | 167,08k | Sale to Issuer | 97,71 | 61,19k | -2,72% |
| 2025-09-03 | Mr. Antonio R. PeraIndependent Director | -7,29k | 692,30k | Verkauf | 94,94 | 22,66k | -24,35% |
| 2025-08-25 | Mr. Matthew J. LeonardIndependent Director | -2,53k | 229,09k | Verkauf | 90,62 | 6,86k | -26,92% |
| 2025-08-22 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,76k | 160,61k | Verkauf | 91,10 | 62,90k | -2,73% |
| 2025-08-20 | Esjay LlcUnternehmen | -100,00k | 9,04M | Verkauf | 90,27 - 90,44 | 431,92k | -18,80% |
| 2025-08-20 | Mr. Antonio R. PeraIndependent Director | -5,42k | 486,43k | Verkauf | 89,73 | 29,95k | -15,33% |
| 2025-08-18 | Ms. Jeanne A. ThomaIndependent Director | -21,54k | 1,92M | Verkauf | 88,87 - 89,76 | 23,41k | -47,93% |
| 2025-08-18 | Mr. Matthew J. LeonardIndependent Director | -6,94k | 611,64k | Verkauf | 88,17 | 9,39k | -42,48% |
| 2025-08-15 | Mr. Patrick D. WalshInsider | -9,00k | 801,45k | Verkauf | 89,05 | 70,05k | -11,39% |
| 2025-08-14 | Esjay LlcUnternehmen | -100,00k | 8,82M | Verkauf | 87,15 - 89,48 | 531,92k | -15,82% |
| 2025-08-15 | Mr. Chad GassertSVP of Corporate Development & Strategy | -20,00k | 1,74M | Verkauf | 86,97 | 246,84k | -7,50% |
| 2025-08-12 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -4,98k | 426,41k | Verkauf | 85,71 | 40,79k | -10,87% |
| 2025-08-12 | Mr. Nikhil LalwaniPresident, CEO & Director | -56,96k | 4,89M | Verkauf | 85,93 | 411,22k | -12,17% |
| 2025-08-12 | Mr. Ori GutwergSVP of Generics | -5,87k | 508,19k | Verkauf | 86,53 | 84,02k | -6,53% |
| 2025-08-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 35,55k | Automatic Disposition | 88,87 | 76,47k | -0,52% |
| 2025-08-12 | Mr. Stephen P. CareySenior VP of Finance & CFO | -50,00k | 1,98M | Derivative Exercise and Sale | 46,49 - 86,07 | 180,86k | - |
| 2025-08-12 | Mr. Thomas J. HaugheyIndependent Chairman of the Board | -19,34k | 1,66M | Verkauf | 85,93 | 36,52k | -34,62% |
| 2025-07-18 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -2,07k | 137,31k | Sale to Issuer | 66,30 | 76,87k | -2,62% |
| 2025-07-14 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 25,95k | Automatic Disposition | 64,88 | 78,95k | -0,50% |
| 2025-06-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 24,55k | Automatic Disposition | 61,37 | 79,35k | -0,50% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
